Noel Brown

Noel is currently the Global Head of Talent Attraction & Acquisition with Thermo Fisher Scientific with a team responsible for recruiting across all groups and divisions for APAC, LATAM & Canada and EMEA. In 2014, Noel became their Global Director of Talent Acquisition Operations to set up a global TA Centre of Excellence model supporting HR transformation. Prior to Thermo Fisher, Noel held Talent Acquisition leadership positions at Heineken and Vodafone and spent 10 years in the Asia Pacific region, and is now based in Glasgow, UK.

Noel is a Chartered Fellow of CIPD (Chartered FCIPD) and Fellow Certified Practitioner Human Resources (FCPHR). 

 

We’re at the heart of the global response to COVID-19, a powerful reminder of our mission to enable our customers to make the world healthier,cleaner and safer. What’s driving us every day is the feeling that there is a meaning to our work over and beyond the reward of the paycheck. What’s compelling now is that we see more people that are framing their careers in a different light. Many people that work in roles outside of typical life science areas are now considering this industry for the first time ever, and they are starting to see that they can transfer their skills from other industries and make an impact in the life sciences sector – a mindset shift that expands the talent pool for the MedTech and Life Science industry. Like many other organisations within our sector, we have accelerated projects scheduled to take months and years to a timeline of a few days and weeks, and this in all aspects of the COVID-19 response, including virus research, diagnostic testing components and capabilities, PPE, vaccine and therapy production. Considering the breadth of this value chain, we’ve had to significantly increase our hiring in certain areas to meet this unprecedented demand. Our requisition volume is up 100% over last year and we are hiring at a speed and scale historically never seen. Looking ahead, the investment in healthcare systems will continue, driven by governments on a national level to bolster capabilities in diagnostics and vaccine development to better protect themselves. There are also large global initiatives like the ‘Access to COVID-19 Tools (ACT) Accelerator’ and COVAX, multi-national collaborations with the involvement of more than two thirds of the world to accelerate development, production, and equitable access to diagnostics, treatments, and vaccines. There will be a huge demand for what we...